Showing results (2391-2400 of 3,011) with videos related to

Sort By:
Pageof 302
Journal of Pharmaceutical Sciences|February 6, 2004
Physical stability of salmon calcitonin spray-dried powders for inhalationHak-Kim Chan, Andrew R Clark, Jane C Feeley, et al.
The Journal of Experimental Medicine|June 16, 2005
Leukotriene B4, an activation product of mast cells, is a chemoattractant for their progenitorsCharlotte L Weller, Sarah J Collington, Jeremy K Brown, et al.
Pediatric Neurology|December 7, 2007
White-matter injury is associated with impaired gaze in premature infantsHannah C Glass, Shinji Fujimoto, Camilla Ceppi-Cozzio, et al.
JACC. Advances|March 18, 2025
Workplace Mistreatment in U.S. Cardiology: A Comprehensive Analysis of Experiences and ImplicationsLaxmi S Mehta, Kevin L Thomas, Anne Rzeszut, et al.
The Journal of Urology|June 1, 1995
Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter studyF Steinbach, A C Novick, H Zincke, et al.
The Journal of Urology|March 29, 2000
Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE databaseG D Grossfeld, J J Chang, J M Broering, et al.
Experimental Neurology|November 29, 2019
The p53 inactivators pifithrin-μ and pifithrin-α mitigate TBI-induced neuronal damage through regulation of oxidative stress, neuroinflammation, autophagy and mitophagyLing-Yu Yang, Nigel H Greig, David Tweedie, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 30, 1988
Triglyceride lowering effect of MaxEPA fish lipid concentrate: a multicentre placebo controlled double blind studyJ P Miller, I D Heath, S K Choraria, et al.
Circulation|November 15, 1995
Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery diseaseK Robinson, E L Mayer, D P Miller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma StudyR I Fisher, E R Gaynor, S Dahlberg, et al.
Pageof 302